Recent progress in the diagnosis and treatment of multiple sclerosis

Journal of Clinical Neuroscience

Volumn 6, Issue 5, 1999, Pages 367-372

  Pender, Michael P ^a,b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Axonal damage; Copolymer 1; Corticosteroid therapy; Immunoglobulin therapy; Interferon beta; Magnetic resonance imaging; Methotrexate; Multiple sclerosis

Indexed keywords

EID: 0008629333     PISSN: 09675868     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0967-5868(99)90026-7     Document Type: Review

References (58)

1. Martin R, McFarland HF. Immunological aspects of experimental allergic encephalomyelitis and multiple sclerosis. Crit Rev Clin Lab Sci 1995; 32: 121-182.
2. Pender MP. Multiple sclerosis. In: Pender MP, McCombe PA (Eds). Autoimmune Neurological Disease. Cambridge: Cambridge University Press, 1995; 89-154.
3. Poser CM, Paty DW, Scheinberg L et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227-231.
4. O'Riordan JI, Thompson AJ, Kingsley DPE et al. The prognostic value of brain MRI in clinically isolated syndromes of the CNS: a 10-year follow-up. Brain 1998; 121: 495-503.
5. Barkhof F, Filippi M, Miller DH et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 1997; 120: 2059-2069.
6. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996; 46: 907-911.
7. Thompson AJ, Polman CH, Miller DH et al. Primary progressive multiple sclerosis. Brain 1997; 120: 1085-1096.
8. McDonnell GV, Hawkins SA. Application of the Poser criteria in primary progressive multiple sclerosis. Ann Neurol 1997; 42: 982-983.
9. Thorpe JW, Kidd D, Moseley IF et al. Spinal MRI in patients with suspected multiple sclerosis and negative brain MRI. Brain 1996; 119: 709-714.
10. Charcot M. Histologie de la sclerose en plaques. Gaz Hosp 1868; 141: 554-555, 557-558.
11. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mörk S, Bö L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 338: 278-285.
12. Ferguson B, Matyszak MK, Esiri MM, Perry VH. Axonal damage in acute multiple sclerosis lesions. Brain 1997; 120: 393-399.
13. Losseff NA, Webb SL, O'Riordan JI et al. Spinal cord atrophy and disability in multiple sclerosis: a new reproducible and sensitive MRI method with potential to monitor disease progression. Brain 1996; 119: 701-708.
14. Davie CA, Barker GJ, Webb S et al. Persistent functional deficit in multiple sclerosis and autosomal dominant cerebellar ataxia is associated with axon loss. Brain 1995; 118: 1583-1592.
15. Losseff NA, Wang L, Lai HM et al. Progressive cerebral atrophy in multiple sclerosis: a serial MRI study. Brain 1996; 119: 2009-2019.
16. 1 spin-echo MRI correlates with disease progression in multiple sclerosis. Neurology 1996; 47: 1469-1476.
17. Van Walderveen MAA, Kamphorst W, Scheltens P et al. Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis. Neurology 1998; 50: 1282-1288.
18. Pender MP. Genetically determined failure of activation-induced apoptosis of autoreactive T cells as a cause of multiple sclerosis. Lancet 1998; 351: 978-981.
19. Sheean GL, Murray NMF, Rothwell JC, Miller DH, Thompson AJ. An electrophysiological study of the mechanism of fatigue in multiple sclerosis. Brain 1997; 120: 299-315.
20. 18F-fluorodeoxyglucose positron emission tomography study. Neurology 1997; 48: 1566-1571.
21. Callanan MM, Logsdail SJ, Ron MA, Warrington EK. Cognitive impairment in patients with clinically isolated lesions of the type seen in multiple sclerosis: a psychometric and MRI study. Brain 1989; 112: 361-374.
22. Milligan NM, Newcombe R, Compston DAS. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. clinical effects. J Neurol Neurosurg Psychiatry 1987; 50: 511-516.
23. Durelli L, Cocito D, Riccio A et al. High-dose intravenous methylprednisolone in the treatment of multiple sclerosis: clinical-immunologic correlations. Neurology 1986; 36: 238-243.
24. Beck RW, Cleary PA, Anderson MM et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. N Engl J Med 1992; 326: 581-588.
25. Oliveri RL, Valentino P, Russo C et al. Randomized trial comparing two different high doses of methylprednisolone in MS: a clinical and MRI study. Neurology 1998; 50: 1833-1836.
26. Barnes D, Hughes RAC, Morris RW et al. Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis. Lancet 1997; 349: 902-906.
27. Sellebjerg F, Frederiksen JL, Nielsen PM, Olesen J. Double-blind, randomized, placebo-controlled study of oral, high-dose methylprednisolone in attacks of MS. Neurology 1998; 51: 529-534.
28. Alam SM, Kyriakides T, Lawden M, Newman PK. Methylprednisolone in multiple sclerosis: a comparison of oral with intravenous therapy at equivalent high dose. J Neurol Neurosurg Psychiatry 1993; 56: 1219-1220.
29. Barkhof F, Polman C. Oral or intravenous methylprednisolone for acute relapses of MS? Lancet 1997; 349: 893-894.
30. The IFNB Multiple Sclerosis Study Group. Interferon beta-lb is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655-661.
31. Paty DW, Li DKB, the UBC MS/MRI Study Group, the IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 662-667.
32. The IFNB Multiple Sclerosis Study Group, the University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995; 45: 1277-1285.
33. Stone LA, Frank JA, Albert PS et al. The effect of interferon-β on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis. Ann Neurol 1995; 37: 611-619.
34. Katz D, Taubenberger JK, Cannella B, McFarlin DE, Raine CS, McFarland HF. Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis. Ann Neurol 1993; 34: 661-669.
35. Kermode AG, Thompson AJ, Tofts P et al. Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis: pathogenetic and clinical implications. Brain 1990; 113: 1477-1489.
36. Lublin FD, Whitaker JN, Eidelman BH, Miller AE, Arnason BGW, Burks JS. Management of patients receiving Interferon beta-1b for multiple sclerosis: report of a consensus conference. Neurology 1996; 46: 12-18.
37. The IFNB Multiple Sclerosis Study Group, the University of British Columbia MS/MRI Analysis Group. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-lb: experience during the first three years. Neurology 1996; 47: 889-894.
38. Pachner AR. Anticytokine antibodies in beta interferon-treated MS patients and the need for testing: plight of the practicing neurologist. Neurology 1997; 49: 647-650.
39. Jacobs LD, Cookfaïr DL, Rudick RA et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996; 39: 285-294.
40. Rudick RA, Simonian NA, Alam JA et al. Incidence and significance of neutralizing antibodies to interferon beta-la in multiple sclerosis. Neurology 1998: 50: 1266-1272.
41. Cross AH, Antel JP. Antibodies to beta-interferons in multiple sclerosis: can we neutralize the controversy? Neurology 1998; 50: 1206-1208.
42. PRISMS (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet 1998; 352: 1498-1504.
43. Munafo A, Trinchard-Lugan I, Nguyen TXQ, Buraglio M. Comparative pharmacokinetics and pharmacodynamics of recombinant human interferon beta-1a after intramuscular and subcutaneous administration. Eur J Neurol 1998; 5: 187-193.
44. European Study Group on Interferon β-1b in Secondary Progressive MS. Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998; 352: 1491-1497.
45. Calabresi PA, Tranquill LR, Dambrosia JM et al. Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon β-1b. Ann Neurol 1997; 41: 669-674.
46. Calabresi PA, Pelfrey CM, Tranquill LR, Maloni H, McFarland HF. VLA-4 expression on peripheral blood lymphocytes is downregulated after treatment of multiple sclerosis with interferon beta. Neurology 1997; 49: 1111-1116.
47. Rudick RA, Ransohoff RM, Lee J-C et al. In vivo effects of interferon beta-1a on immunosuppressive cytokines in multiple sclerosis. Neurology 1998; 50: 1294-1300.
48. Bornstein MB, Miller A, Slagle S et al. A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. N Engl J Med 1987; 317: 408-414.
49. Johnson KP, Brooks BR, Cohen JA et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 1995; 45: 1268-1276.
50. Fazekas F, Deisenhammer F, Strasser-Fuchs S, Nahler G, Mamoli B. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Lancet 1997; 349: 589-593.
51. Achiron A, Gabbay U, Gilad R et al. Intravenous immunoglobulin treatment in multiple sclerosis: effect on relapses. Neurology 1998; 50: 398-402.
52. Sorensen PS, Wanscher B, Jensen CV et al. Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology 1998; 50: 1273-1281.
53. Yudkin PL, Ellison GW, Ghezzi A et al. Overview of azamioprine treatment in multiple sclerosis. Lancet 1991; 338: 1051-1055.
54. The Multiple Sclerosis Study Group. Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: a randomized, double-blinded, placebo-controlled clinical trial. Ann Neurol 1990; 27: 591-605.
55. Pender MP. Cyclosporine and multiple sclerosis. Ann Neurol 1991; 29: 226.
56. Goodkin DE, Rudick RA, VanderBrug Medendorp S et al. Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann Neurol 1995; 37: 30-40.
57. Goodkin DE, Rudick RA, VanderBrug Medendorp S, Daughtry MM, Van Dyke C. Low-dose oral methotrexate in chronic progressive multiple sclerosis: analyses of serial MRIs. Neurology 1996; 47: 1153-1157.
58. Rudick RA, Cohen JA, Weinstock-Guttman B, Kinkel RP, Ransohoff RM. Management of multiple sclerosis. N Engl J Med 1997; 337: 1604-1611.